Literature DB >> 2933122

Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.

J Waxman, A Man, W F Hendry, H N Whitfield, G M Besser, R C Tiptaft, A M Paris, R T Oliver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2933122      PMCID： PMC1419017          DOI： 10.1136/bmj.291.6506.1387

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

2.  Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?

Authors:  V Borgmann; W Hardt; M Schmidt-Gollwitzer; H Adenauer; R Nagel
Journal:  Lancet       Date:  1982-05-15       Impact factor: 79.321

3.  Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

Authors:  J H Waxman; J A Wass; W F Hendry; H N Whitfield; G M Besser; J S Malpas; R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23
  3 in total
  29 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2006

3.  Hormonal manipulation of prostatic cancer.

Authors:  F H Schröder
Journal:  BMJ       Date:  1991-12-14

4.  GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Authors:  Shaolin Ma; Sunila Pradeep; Alejandro Villar-Prados; Yunfei Wen; Emine Bayraktar; Lingegowda S Mangala; Mark Seungwook Kim; Sherry Y Wu; Wei Hu; Cristian Rodriguez-Aguayo; Carola Leuschner; Xiaoyan Liang; Prahlad T Ram; Katharina Schlacher; Robert L Coleman; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

Review 5.  Prostate cancer.

Authors:  D Mazhar; J Waxman
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 6.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

Review 7.  The andropause: fact or fiction?

Authors:  N Burns-Cox; C Gingell
Journal:  Postgrad Med J       Date:  1997-09       Impact factor: 2.401

Review 8.  Gonadotrophin hormone releasing analogues open new doors in cancer treatment.

Authors:  J Waxman
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-31

Review 9.  Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.

Authors:  R N Brogden; P Chrisp
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

Review 10.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.